Protagonist Therapeutics Reports Granting of Inducement Awards
-
S. Korea's impeached President Yoon holds out in capital 'fortress'
-
Samsung warns fourth-quarter profit to miss forecasts
-
China's viral wild boar hunters attract fame and concern
-
Forgotten but not gone: Covid keeps killing, five years on
-
Is the world ready for the next pandemic?
-
Trump's provocative, often confusing, US foreign policy is back
-
Rescuers search for survivors after quake in China's Tibet kills at least 126
-
Brazil gears up for first climate conference in Amazon
-
In Brazil, an Amazon reforestation project seeks to redeem carbon markets
-
Djokovic with point to prove against younger rivals at Australian Open
-
Asian markets mixed after Wall St hit by US inflation fears
-
Mexicans offered $1,300 to hand in a machine gun
-
Venezuela arrests two Americans, five other 'mercenaries'
-
Iraqi archaeologists piece together ancient treasures ravaged by IS
-
Big Tech rolls out the red carpet for Trump
-
Kyrgios suffers new injury setback days before Australian Open
-
Former US president Carter lies in state after somber Washington procession
-
US company Firefly Aerospace to launch for Moon next week
-
Don't eat your Christmas tree, warns Belgium food agency
-
No proof fentanyl produced in Mexico, president says
-
Mosquitoes with 'toxic' semen could stem disease spread: research
-
NFL's Raiders fire head coach Pierce
-
Deschamps to step down as France coach after 2026 World Cup: team source
-
Newcastle win at Arsenal to put one foot in League Cup final
-
Race begins to replace Canadian PM Trudeau
-
Wildfire sparks panicked evacuations in Los Angeles suburb
-
NASA eyes SpaceX, Blue Origin to cut Mars rock retrieval costs
-
Eyeing green legacy, Biden declares new US national monuments
-
Venezuela's Gonzalez Urrutia says son-in-law detained in new clampdown
-
Invisible man: German startup bets on remote driver
-
Turkey threatens military operation against Syrian Kurdish fighters
-
Second accused in Liam Payne drug death surrenders: Argentine police
-
Disinformation experts slam Meta decision to end US fact-checking
-
Freewheeling Trump sets out US territorial ambitions
-
'Snowball's chance in hell' Canada will merge with US: Trudeau
-
Daglo, feared Darfuri general accused by US of genocide
-
Trump Jr. in Greenland on 'tourist' trip as father eyes territory
-
Chat leaves Racing by 'mutual consent' after Christmas party incident
-
TVs get smarter as makers cater to AI lifestyles
-
Peter Yarrow of Peter, Paul and Mary dead at 86
-
Dyche accepts Everton job under scrutiny from new owners
-
US urged to do more to fight bird flu after first death
-
Trump says NATO members should raise defense spending to 5% of GDP
-
X's 'Community Notes': a model for Meta?
-
Freewheeling Trump sets out territorial ambitions
-
England skipper Stokes undergoes hamstring operation
-
Inflation concerns pull rug out from Wall Street rally
-
Ban for Wolves striker Cunha cut after offer to buy new glasses for security guard
-
Olmo situation could affect future signings: Barca's Raphinha
-
US sanctions top Hungary minister over 'corruption'
NYSE - LSE
| RIO | -0.33% | 58.19 | $ | |
| RBGPF | 100% | 59.31 | $ | |
| CMSC | -1.12% | 23.23 | $ | |
| NGG | -0.46% | 58.6 | $ | |
| GSK | 0.38% | 34.09 | $ | |
| SCS | -2.14% | 11.2 | $ | |
| RELX | 0.72% | 45.98 | $ | |
| BTI | -0.52% | 36.78 | $ | |
| CMSD | -1.15% | 23.46 | $ | |
| BCC | -1.69% | 118.22 | $ | |
| JRI | -1.88% | 12.22 | $ | |
| BP | 2.54% | 31.83 | $ | |
| RYCEF | -0.42% | 7.17 | $ | |
| BCE | -0.34% | 23.86 | $ | |
| AZN | -0.3% | 66.64 | $ | |
| VOD | -0.71% | 8.41 | $ |
Protagonist Therapeutics Reports Granting of Inducement Awards
Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on January 2, 2025, it issued inducement awards to Newman Yeilding, M.D., upon his appointment to the role of Executive Vice President, Chief Scientific Officer, in accordance with the terms of his employment offer letter. Dr. Yeilding served in a consultant role as the Company's Chief Scientific Advisor from August 1, 2024 through January 1, 2025. The awards were granted under the Protagonist Therapeutics Amended and Restated Inducement Plan, which was adopted May 29, 2018, and amended February 18, 2020 and February 15, 2022.
Dr. Yeilding received options to purchase 38,520 shares and restricted stock units (RSUs) to acquire 31,779 shares of Protagonist Therapeutics common stock. The exercise price of the options is $38.98, which was the per-share closing price of Protagonist Therapeutics common stock on the Nasdaq Global Market on January 2, 2025. The shares subject to the option vest over a four-year period, with 25 percent of the shares subject to the option vesting on the first anniversary of Dr. Yeilding's date of hire and the remainder vesting in equal monthly installments over three years thereafter. One-fourth of the shares underlying the RSUs will vest annually over a four-year period. The awards were approved by the compensation committee of the Company's board of directors and were granted as a material inducement to Dr. Yeilding's entering into employment with the Company in accordance with Nasdaq Marketplace Rule 5635(c)(4).
About Protagonist Therapeutics
Protagonist Therapeutics is a late-stage development biopharmaceutical company focused on peptide therapeutics. Two novel peptides derived from Protagonist's proprietary discovery platform are currently in advanced Phase 3 clinical development, with New Drug Application submissions to the FDA potentially in 2025. Icotrokinra (JNJ-2113, formerly PN-235), licensed to Johnson & Johnson, is the first targeted oral peptide designed to selectively block the IL-23 receptor. Icotrokinra has successfully completed two Phase 3 psoriasis (PsO) studies (ICONIC-LEAD and ICONIC-TOTAL) and is currently in three additional Phase 3 PsO studies (ICONIC-ADVANCE 1, ICONIC-ADVANCE 2, and a Postular/Erythrodermic PSO study) and a Phase 2b ulcerative colitis study (ANTHEM-UC). Rusfertide, a mimetic of the natural hormone hepcidin, is currently in Phase 3 development for the rare blood disorder polycythemia vera. Rusfertide is being co-developed and will be co-commercialized with Takeda Pharmaceuticals pursuant to a worldwide collaboration and license agreement entered into in 2024 under which the Company remains primarily responsible for development through NDA filing. The Company also has a number of pre-clinical stage oral drug discovery programs addressing clinically and commercially validated targets, including IL-17 oral peptide antagonist PN-881, oral anti-obesity peptides, and an oral hepcidin mimetic/ferroportin blocker.
More information on Protagonist, its pipeline drug candidates and clinical studies can be found on the Company's website at www.protagonist-inc.com.
Contact Information
Corey Davis Ph.D.
Investor Relations Contact - LifeSci Advisors
[email protected]
+1 212 915 2577
Virginia Amann
Media Relations Contact - ENTENTE Network of Companies
[email protected]
+1 833 500 0061 ext 1
SOURCE: Protagonist Therapeutics
P.Silva--AMWN